Bespak Embarks On New Journey With Focus On Sustainable Inhaler Solutions

In a significant move within the pharmaceutical and healthcare sectors, Bespak has recently completed a strategic transaction that marks its separation from the Recipharm Group, establishing itself as a standalone entity. This development is backed by EQT Private Equity and heralds the creation of a leading global contract development and manufacturing organisation (CDMO) with a focus on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.

Historically known for its expertise in pressurised Metered Dose Inhaler (pMDI) dosing valves and actuators, along with complex Dry Powder Inhaler (DPI) devices, Bespak's origins trace back to its King’s Lynn, UK site. The newly independent Bespak Group now encompasses three sites, broadening its capabilities significantly. This includes an early-stage laboratory in North Carolina, U.S., boasting over two decades of experience in feasibility, analytical, and product development services for inhaled and nasal drug products. Additionally, its Holmes Chapel, UK site has been pivotal in the scale-up and clinical and commercial supply of pMDIs and nasal drug-device combination products since the 1960s.

Chris Hirst, previously President of the Advanced Delivery Systems Business Unit at Recipharm, steps into the role of CEO at Bespak. Under his leadership, the company is positioned as a trusted innovation partner with a commitment to sustainability, particularly in transitioning to greener inhalers. Kåre Schultz, with a distinguished career including roles such as CEO of Teva Pharmaceutical Industries and Chairman of Royal Unibrew, has been appointed Chairman of the Board of Directors at Bespak.

Bespak has also announced a substantial investment in expanding manufacturing capacity at its Holmes Chapel site. This expansion includes the installation of commercial-scale and pilot-scale filling lines for pMDIs using HFA-152a propellant. This propellant is noted for its significantly lower Global Warming Potential (GWP) compared to currently used propellants. This initiative underscores Bespak's dedication to meeting the growing demand for greener inhaler options among global pharmaceutical companies.

This announcement follows a landmark achievement last year when the Holmes Chapel site became the first CDMO to manufacture a pMDI at commercial scale using HFO-1234ze, a near-zero GWP propellant. This development is part of broader efforts to phase down current hydrofluoroalkane (HFA) propellants in response to legislation aimed at limiting global warming.

Chris Hirst emphasized Bespak's commitment to leading the transition to low GWP propellants in pMDIs. He highlighted that this investment positions Bespak uniquely as the only CDMO—and indeed the only site—in the world capable of manufacturing at scale with both new green propellants: HFA-152a and HFO-1234ze.

Matthias Wittkowski from EQT Private Equity’s Advisory Team expressed optimism about Bespak's future growth prospects. He lauded the experienced team led by Chris Hirst and underscored EQT's support for Bespak in its next growth phase. The separation from Recipharm and subsequent formation of an independent company focused on advancements in inhaled and nasal drug delivery represent a pivotal moment for Bespak. It sets a strong foundation for future growth and offers a unique opportunity for the industry to advance towards greater sustainability.